Prostate (BPH), Bladder & Urinary Tract • ICD-10-CM N20.1
Calculus of ureter
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM N20.1 • 2 Linked .gov / PubMed Citations
•
Governance: Dr. Julian Sterling, MD, FACS (NPI #1376841536)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Calculus of ureter Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as N20.1, Calculus of ureter falls under Urology & Prostate management, where alpha-1 blockers [Calculus of ureter N20.1] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Calculus of ureter uses ICD-10 N20.1 across Urology & Prostate specialty care.
- 3 Typical cash cost range: Workup highlights for Calculus of ureter (N20.1): alpha-1 blockers [Calculus of ureter N20.1].
- 4 Top reported side effects / signs: Objective lab/clinical target for Calculus of ureter: IPSS Urinary Symptom in Calculus of ureter (N20.1: Score) (0 – 7 (mild symptoms) (N20.1)) and Urinalysis & Post-Void in Calculus of ureter (N20.1: Residual (PVR)).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Calculus of ureter
What Is Calculus of ureter?
Designated in federal medical registries as N20.1, Calculus of ureter falls under Urology & Prostate management, where alpha-1 blockers [Calculus of ureter N20.1] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in urology & prostate, Calculus of ureter (N20.1) involves uropathogenic bacterial mucosal in Calculus of ureter (N20.1: adherence (cystitis) or). progression correlates with shifts in IPSS Urinary Symptom in Calculus of ureter (N20.1: Score) (0 – 7 (mild symptoms) (N20.1)).
Common Symptoms & Clinical Signs
- • Presentation of Calculus of ureter (N20.1): sudden severe flank-to-groin in Calculus of ureter (N20.1: colicky pain caused)
- • Secondary Calculus of ureter clinical sign: weak, hesitant, or in Calculus of ureter (N20.1: intermittent urinary stream)
- • Symptom flares in Calculus of ureter correlating with IPSS Urinary Symptom in Calculus of ureter (N20.1: Score) deviation outside 0 – 7 (mild symptoms) (N20.1)
- • Functional urology & prostate impact requiring alpha-1 blockers [Calculus of ureter N20.1] evaluation (N20.1)
Calculus of ureter Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N20.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Prostate (BPH), Bladder & Urinary Tract | NLM Clinical Tables |
| Diagnostic / Lab Marker: IPSS Urinary Symptom in Calculus of ureter (N20.1: Score) | 0 – 7 (mild symptoms) (N20.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urinalysis & Post-Void in Calculus of ureter (N20.1: Residual (PVR)) | Negative leukocyte/nitrite; PVR < 50 mL (N20.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total PSA & in Calculus of ureter (N20.1: Serum Creatinine/eGFR) | Age-specific PSA; eGFR > 75 mL/min (N20.1) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Calculus of ureter
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Fluocinolone Acetonide Topical Solution USP, 0.01% Fluocinolone Acetonide Topical Solution USP, 0.01% Generic • RxCUI 1191310 | Corticosteroid | 88% | $0.1860 | $ 16.03 /mo |
| Olaparib Lynparza • RxCUI RXN-03100569-2404 | Poly(ADP-Ribose) Polymerase Inhibitor | 88% | $2.0200 | $ 90.31 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Calculus of ureter)
Human clinical trial evidence for Calculus of ureter is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Zero-PHI Patient Support & Cohort Discussions
Calculus of ureter Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Calculus of ureter community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Calculus of ureter.